Serina Therapeutics (NYSEAMERICAN:SER – Get Free Report)‘s stock had its “buy” rating reaffirmed by research analysts at BTIG Research in a report released on Monday, Benzinga reports. They currently have a $8.00 price objective on the stock. BTIG Research‘s price target would indicate a potential upside of 367.84% from the stock’s current price.
Serina Therapeutics Stock Up 3.6%
Serina Therapeutics stock traded up $0.06 during trading hours on Monday, hitting $1.71. 38,283 shares of the stock traded hands, compared to its average volume of 1,431,773. The firm’s 50-day moving average price is $2.24 and its two-hundred day moving average price is $2.08. The company has a current ratio of 6.65, a quick ratio of 6.65 and a debt-to-equity ratio of 0.16. The company has a market cap of $43.43 million, a PE ratio of -0.90 and a beta of 1.19. Serina Therapeutics has a one year low of $1.22 and a one year high of $5.25.
Serina Therapeutics (NYSEAMERICAN:SER – Get Free Report) last released its earnings results on Thursday, August 13th. The company reported ($0.55) EPS for the quarter.
Serina Therapeutics Company Profile
Serina Therapeutics is a clinical-stage biopharmaceutical company developing medicines designed to provide longer-lasting and more consistent therapeutic effects. The company uses its proprietary POZ polymer technology to modify existing drug compounds, with the goal of extending their duration of action and potentially improving treatment convenience and tolerability.
Serina’s lead program is POZ-apomorphine, also referred to as SER-252, an investigational therapy being developed for patients with advanced Parkinson’s disease.
Featured Articles
- Five stocks we like better than Serina Therapeutics
- Comfort Systems Earnings: AI Slowdown or More Growth Ahead?
- Bristol Myers Squibb’s Cancer Breakthrough Could Have Implications Beyond Its Own Stock
- 5 Beaten-Down Growth Stocks Trading Like Value Plays as Cash Chases Mega-Caps
- Anthropic’s IPO Filing Reveals a Massive Opportunity for AI Infrastructure Giants
Receive News & Ratings for Serina Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Serina Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.
